Semaglutide vs Tirzepatide 2026: Complete Research Comparison

Semaglutide (Novo Nordisk's Ozempic/Wegovy) and Tirzepatide (Eli Lilly's Mounjaro/Zepbound) are the two dominant GLP-1 receptor agonists in the global pharmaceutical market. Both have achieved blockbuster status, but they differ in important ways that researchers should understand.

This comparison is based entirely on published clinical trial data — primarily the SUSTAIN, STEP, SURPASS, and SURMOUNT trial programmes — and peer-reviewed publications. We compare mechanisms, efficacy, safety, and research implications.

Peptides Pharma offers Tirzepatide in two research formats: the Research Vial (10mg, €139) and Tirzepatide Vial (40mg prefilled, €249). Semaglutide is not currently in the Peptides Pharma range.

Semaglutide: GLP-1 Receptor Agonist (single) Semaglutide is a selective GLP-1 (glucagon-like peptide-1) receptor agonist. It: - Stimulates insulin secretion (glucose-dependent) - Suppresses glucagon release - Slows gastric emptying - Acts on hypothalamic appetite centres to reduce hunger - Has a half-life of approximately 7 days (enabling weekly dosing)

Tirzepatide: GIP/GLP-1 Dual Receptor Agonist Tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors: - All the GLP-1 effects listed above - Additionally: GIP receptor activation enhances insulin sensitivity, promotes fat oxidation, and may contribute to greater weight loss through complementary metabolic pathways - GIP receptor activity may also modulate bone metabolism and cardiovascular function - Half-life: approximately 5 days (weekly dosing)

The key difference: Tirzepatide's dual mechanism targets two incretin pathways simultaneously, while semaglutide targets one. This dual agonism is believed to explain tirzepatide's superior efficacy observed in head-to-head trials.

The SURPASS-2 trial directly compared tirzepatide to semaglutide 1mg in patients with Type 2 diabetes — providing the most definitive head-to-head data available.

HbA1c reduction (40 weeks): - Semaglutide 1mg: -1.86% - Tirzepatide 5mg: -2.01% - Tirzepatide 10mg: -2.24% - Tirzepatide 15mg: -2.30%

All three tirzepatide doses produced statistically superior HbA1c reductions compared to semaglutide 1mg.

Body weight reduction (40 weeks): - Semaglutide 1mg: -5.7 kg - Tirzepatide 5mg: -7.6 kg - Tirzepatide 10mg: -9.3 kg - Tirzepatide 15mg: -11.2 kg

Tirzepatide 10mg and 15mg produced significantly greater weight loss than semaglutide 1mg.

Important caveat: This trial compared tirzepatide to semaglutide 1mg. Semaglutide is available at 2.4mg for weight management (Wegovy). A direct comparison of tirzepatide 15mg vs semaglutide 2.4mg has not been published in a head-to-head trial as of March 2026, though indirect comparisons (SURMOUNT vs STEP data) suggest tirzepatide maintains a numerical advantage.

While not head-to-head, comparing the flagship weight loss trials provides useful context:

STEP 1 (Semaglutide 2.4mg, obesity without diabetes): - Mean weight loss at 68 weeks: -14.9% (vs -2.4% placebo) - Participants achieving ≥5% loss: 86.4% - Participants achieving ≥10% loss: 69.1% - Participants achieving ≥20% loss: 32.0%

SURMOUNT-1 (Tirzepatide 15mg, obesity without diabetes): - Mean weight loss at 72 weeks: -22.5% (vs -2.4% placebo) - Participants achieving ≥5% loss: 96.3% - Participants achieving ≥10% loss: 89.4% - Participants achieving ≥20% loss: 56.7% - Participants achieving ≥25% loss: 36.2%

Comparison summary (not head-to-head): | Metric | Semaglutide 2.4mg | Tirzepatide 15mg | |--------|-------------------|------------------| | Mean weight loss | 14.9% | 22.5% | | ≥10% loss achieved | 69.1% | 89.4% | | ≥20% loss achieved | 32.0% | 56.7% |

Tirzepatide shows numerically superior weight loss across all metrics, though cross-trial comparisons have inherent limitations (different patient populations, trial designs, and timepoints).

Note: These are pharmaceutical clinical trial results. Peptides Pharma's Tirzepatide research products are sold for research purposes only.

Both compounds share a similar gastrointestinal side effect profile, as expected from their GLP-1 activity:

Gastrointestinal side effects (most common): | Side Effect | Semaglutide 2.4mg | Tirzepatide 15mg | |-------------|-------------------|------------------| | Nausea | 44% | 25-31% | | Diarrhoea | 30% | 17-23% | | Vomiting | 24% | 12-18% | | Constipation | 24% | 11-17% |

Key observation: Tirzepatide appears to have a somewhat lower incidence of GI side effects compared to semaglutide at maximally effective doses, despite producing greater weight loss. This may be related to the GIP component's modulatory effects on gastric motility.

Serious adverse events (both compounds): - Pancreatitis: Rare (<1%) for both - Gallbladder events: Rare for both - Thyroid C-cell tumours: Theoretical risk based on animal data; both carry boxed warnings - Hypoglycaemia: Low risk (primarily when combined with insulin/sulfonylureas)

Discontinuation due to adverse events: - Semaglutide (STEP trials): ~7% - Tirzepatide (SURMOUNT trials): ~6-7%

Both compounds are generally well-tolerated when properly dose-titrated.

Based on the available evidence:

Tirzepatide advantages: - Superior weight loss in both direct (SURPASS-2) and indirect (SURMOUNT vs STEP) comparisons - Dual mechanism (GIP + GLP-1) provides a unique research model - Potentially lower GI side effect burden at effective doses - Novel mechanism opens new research avenues (GIP receptor biology) - Broader metabolic improvements observed in some metrics

Semaglutide advantages: - Longer track record (approved earlier) - More published long-term safety data - Available in oral formulation (Rybelsus) — unique among GLP-1 agonists - Cardiovascular outcome data (SELECT trial) — demonstrated CV risk reduction - More widely available globally

For UK researchers: Tirzepatide's dual agonist mechanism makes it a particularly interesting research compound — it allows investigation of GIP receptor biology alongside GLP-1 effects. The superior efficacy data adds to its research appeal.

Peptides Pharma offers Tirzepatide in two research formats: - Research Vial (10mg, €139): Allows dose titration for research protocols exploring dose-response relationships - Tirzepatide Vial (40mg prefilled, €249): Single-use format for standardised weekly dosing research

Both include >99% purity verification, batch-specific COA, and free UK shipping.